Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMELIE: Apatinib and Etoposide vs Paclitaxel in Platinum-Resistant Ovarian Cancer
NCT04000295Phase 3Unknown
- Sponsor
- Hengrui
- Start
- Aug 2019
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Rivoceranib in ovarian cancer, sponsored by Hengrui. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT04000295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04000295.